Breaking Canadian GLP-1 news
GLP-1 News
Drug approvals, price changes, generic timelines, and clinical trial results affecting GLP-1 medication costs in Canada.
Health Canada Approves Sevmia (Apotex): Canada’s First Generic Wegovy
Health Canada approved Sevmia (Apotex) on June 29, 2026 — the first generic version of Wegovy and the first generic semaglutide cleared for weight management in Canada. Pricing has not been published yet.
Pharmacy-Level Generic Semaglutide Switch Mechanics Detailed
Endor Health details how Canadian pharmacies will substitute generic semaglutide at refill, with pCPA tiers setting public-plan prices at 85% down to 35% of brand.
Sandoz Cites Brazil Priority Review as Canada Wait Stretches On
Sandoz Canada points to Brazil's proactive prioritization of generic semaglutide submissions as the Canadian regulator continues to send back questions a year after filing.
Health Canada Review Cites 7.1M GLP-1 Prescriptions in 2023
Health Canada's Summary Safety Review discloses 7.1 million GLP-1 receptor agonist prescriptions dispensed by Canadian retail pharmacies in 2023.
Federal Budget Skips Health Canada Generic Backlog Fix: CGPA
Canada's federal budget omitted new Health Canada resources to clear a generic drug backlog, drawing criticism from CGPA's Jim Keon as semaglutide files queue.
Alberta Blue Cross: GLP-1 Plan Spend Won't Fall Despite Generic
Alberta Blue Cross's 2026 pipeline report says GLP-1 plan spend is unlikely to fall despite a mid-2026 semaglutide generic, citing expanding uses and growing demand.
Novo Nordisk Details SOUL Trial Behind Rybelsus MACE Approval
Novo Nordisk Canada president Vince Lamanna detailed the SOUL trial of 9,650 patients behind Health Canada's MACE indication expansion for Rybelsus tablets.
Seven Generic Semaglutide Files Remain Under Health Canada Review
Health Canada is reviewing seven additional generic semaglutide submissions after Dr. Reddy's and Apotex authorizations, with more decisions expected in coming weeks.
Novo Nordisk Aligns Brand Ozempic Price With Generics in Canada
Novo Nordisk cuts brand-name Ozempic pricing for uninsured Canadians via its Savings Card, aligning costs with newly arrived generics from Apotex and Dr. Reddy's.
Eli Lilly Raises Mounjaro Prices in Canada Amid Trump Pressure
Eli Lilly raised Mounjaro list prices in Canada and Britain after Trump administration pressure, with Kwikpen wholesale prices now ranging $387 to $773.
Health Canada Safety Review: No GLP-1 Suicide Link in T2D Patients
Health Canada's Summary Safety Review found no evidence linking GLP-1 receptor agonists to suicide or self-harm in type 2 diabetes patients; obesity data inconclusive.
Apotex, Dr Reddy's Map Divergent Global Paths for Generic Semaglutide
Apotex CEO Martin Arès says the company is exploring US access routes while Dr Reddy's targets 80+ countries excluding US, UK and Europe.
TrumpRx Starts at US$350, Phases to US$245 as Canada Goes Generic
TrumpRx will sell GLP-1s starting at US$350, dropping to US$245 over two years, while Canada has approved two generic semaglutides, CBC and BMJ report.
Dr. Reddy's Generic Semaglutide Cleared NOD, NON Before Approval
Health Canada's Regulatory Decision Summary reveals Dr. Reddy's generic semaglutide cleared a Notice of Deficiency and Notice of Non-Compliance before April 28 approval.
Novo Nordisk Rebrands: Plosbrio, Poviztra Approved Dec 22, 2025
Health Canada approved two Novo Nordisk rebranded semaglutide products, Plosbrio and Poviztra, on December 22, 2025, as a defensive move against generics.
BBC Profiles Ottawa Patient Paying C$350-C$500 Monthly for Wegovy
BBC profiles Ottawa retiree Elizabeth Doran, 69, who paid C$350-C$500 monthly out of pocket for Wegovy and took substitute teaching shifts to afford it.
BBC: US Patients Eye Canadian Generic Semaglutide as Prices Diverge
BBC reports Americans may look north for generic semaglutide as Canadian patients access generics priced at less than a third of brand cost.
Selectpath Urges Plan Sponsors to Mandate Generic Substitution
Selectpath advisor warns Canadian plan sponsors that lower generic semaglutide prices may not cut total spend without mandatory substitution and tighter prior authorization.
Dr. Reddy's CEO Israeli Frames Canada Launch as Access Mission
Dr. Reddy's CEO Erez Israeli says the company remains dedicated to expanding GLP-1 access in Canada after becoming first to win generic semaglutide approval.
Alberta Blue Cross 2026 Pipeline: GLP-1 'Second Wave' Coming
Alberta Blue Cross's 2026 drug pipeline report flags a second wave of GLP-1 innovation, with MASH and sleep apnea indications keeping plan spend high.
Novo Nordisk: More Than 1 Million Canadians Take Semaglutide
Novo Nordisk says more than a million Canadians take a semaglutide drug, as CGPA reports 500+ generic submissions under Health Canada review with 100+ backlogged.
Health Canada Notice: Seven More Generic Semaglutide Files in Queue
After Apotex became Canada's second generic semaglutide approval on May 1, seven additional generic semaglutide submissions remain under review at Health Canada.
Rexall, Shoppers Expect Generic Semaglutide Shipments This Week
Rexall expects a generic semaglutide shipment by week's end and Shoppers Drug Mart says inventory is arriving at distribution centres and select stores.
Novo Nordisk Savings Card Routes Ozempic Discount Through Rexall
Novo Nordisk Canada's reduced Ozempic price for uninsured patients launches via a Savings Card applied automatically at Novo Nordisk Care Rx by Rexall, excluding Quebec.
Health Canada Hit 180-Day Generic Target 84% of Time in FY25
Health Canada met its 180-day generic review target 84% of the time in fiscal 2024-25 as 500+ submissions sit under review, including seven semaglutide files.
Novo Nordisk Cites 9,650-Patient SOUL Trial Behind Rybelsus Nod
Novo Nordisk's Rybelsus MACE indication in Canada is backed by the 9,650-patient SOUL trial, with President Vince Lamanna calling it an important milestone.
CDA Benchmarks Mounjaro to Ozempic's $228 List Price in Canada
Canada's Drug Agency suggests public plans pay no more for 5 mg Mounjaro than the $228 list price of 1 mg Ozempic, with 25-49% discounts at higher doses.
Obesity Canada Cites $27.6B Untreated Cost in Coverage Pivot
Obesity Canada's Sockalingam ties the $27.6B 2023 untreated-obesity cost and sub-20% private-plan coverage to Canada's G7-first generic semaglutide approval.
Saskatchewan Blue Cross: Generic Semaglutide Doesn't Change Plan Rules
Saskatchewan Blue Cross says coverage rules for semaglutide are not changing after Health Canada's G7-first generic approval, though out-of-pocket costs may fall.
Apotex 2 mg and 4 mg Pens Set to Hit Alberta Shelves 'Any Day'
Apotex told CBC its 2 mg and 4 mg pre-filled generic semaglutide pens will reach Alberta pharmacies 'any day', with stock orders starting this week.
Alberta Pharmacies Begin Ordering Generic Semaglutide This Week
Calgary pharmacist Wessam Sakr was notified he could start ordering generic semaglutide this week, with Apotex pens expected on Alberta shelves any day.
Walk-In Maps Patent Timeline Behind Canada's G7-First Generic
Walk-In Clinic details the 2020 patent lapse, January 2026 data exclusivity end, and March 2026 formulation patent expiry that opened Canada's generic semaglutide path.
CDA Mounjaro Math: Lilly's $300 Floor Meets a 25-49% Discount Ask
Canada's Drug Agency wants 25-49% off higher-dose Mounjaro list prices, even after Eli Lilly's December cut set 2.5 and 5 mg at $300 for four weeks.
BMJ: Canada Is Only the Second Country to Clear Generic Semaglutide
BMJ reports Canada is only the second country in the world to approve a generic semaglutide, with two products cleared and seven more under Health Canada review.
Health Canada Details DIN Checks, CBSA Role in GLP-1 Advisory
Health Canada's January 21 advisory tells buyers to verify GLP-1 drugs via eight-digit DIN and Drug Product Database, and flags CBSA cooperation on shipments.
Endor Health Lists Sandoz, Apotex, Teva, Taro, Aspen in Queue
Endor Health names Sandoz, Apotex, Teva, Taro and Aspen among nine generic semaglutide submissions before Health Canada, citing a 180-day target review.
CMA Explainer Maps Post-Approval Access Path for Canadians
CMA's patient explainer details prescription rules, provincial coverage limits, and what Canadians should expect as generic semaglutide enters pharmacies.
TrumpRx GLP-1 Prices Land at US$350, Above Canadian List Prices
TrumpRx will start GLP-1 sales at US$350 monthly dropping to US$245, while Canadian list prices for Ozempic sit near $228 and Mounjaro $300–$540.
Dr. Reddy's Generic Semaglutide Reached Canadian Pharmacies May 15
Dr. Reddy's generic semaglutide became available in Canada on May 15, 2026, with Shoppers Drug Mart and Rexall confirming inventory arriving at distribution centres.
Where Generic Semaglutide Is Made: Apotex, Dr. Reddy's Detail Sites
Apotex confirms its generic semaglutide injectors will be made in India by a partner with sterile fill capacity, while Dr. Reddy's lists India, UK and Mexico sites.
Insurers Detail How Generic Semaglutide Will Flow Through Plans
Canadian insurers including iA, Beneva, Sun Life and Desjardins outline how generic semaglutide will be reimbursed, with claims paid jumping to $77M in 2024.
Tirzepatide Pricing Path: Lilly's December Cut Meets CDA Review
Eli Lilly's December 2025 Canadian price cut on Mounjaro and Zepbound dropped 2.5 mg and 5 mg doses to a $300 list, ahead of CDA's coverage review.
Apotex Pegs Generic Semaglutide at One-Third of Brand Price
Apotex says its generic semaglutide will land at roughly one-third the price of brand Ozempic as Shoppers Drug Mart and Rexall report inbound shipments.
Vital: Generic Semaglutide Reaching Canada's 10,000+ Pharmacies
Apotex began shipping generic semaglutide Tuesday while Dr. Reddy's reached select Canadian pharmacies; Rexall and Shoppers Drug Mart confirm incoming inventory.
Sandoz's Robidoux: Generic Semaglutide Road 'Longer Than Expected'
Sandoz Canada GM Michel Robidoux says generic semaglutide approval taking longer than expected as Health Canada backlog hits 100+ submissions and 84% target rate.
Generic Semaglutide Enters pCPA Tier at 85% of Brand Reference
Endor Health details how generic semaglutide enters Canada's pCPA framework at 85% of brand reference price, dropping to 55% after three months of public funding.
Felix Health begins offering generic semaglutide at $149/month — what we learned from their Chief Pharmacy Officer
Felix Health's $149/month all-in pricing for generic semaglutide. Exclusive interview with their Chief Pharmacy Officer on the waitlist, supplier, and what's next.
Selectpath Warns Generics May Not Cut Canadian GLP-1 Plan Spend
Benefits advisor Selectpath warns Canadian plan sponsors that generic semaglutide may not lower total drug spend as volume rises with broader eligibility.
BMJ: $250 Unpaid Fee Opened Door to Canada's Generic Semaglutide
BMJ reports Canada is the second country to approve generic semaglutide after Novo Nordisk did not pay a C$250 annual fee, with two generics now shipping.
Generic Semaglutide Queue: Health Canada vs CMA Application Counts
Health Canada lists eight pending generic semaglutide submissions after the Dr. Reddy's approval, while CMA cited nine active applications as of late December 2025.
Looking for current pharmacy prices?
Compare GLP-1 prices across Canada